Introduction/Background Vulva cancer accounts for less than 4% of all gynecological cancers and less than 1% of women’s cancers. In Tunisia, this pathology represents 1.3%–1.6% of gynecological malignant diseases, with an incidence varying from 0.5 to 1.2/100,000 women per year.

Methodology We retrospectively included 192 patients treated for VC at the Salah Azaiez Institute between 1994 and 2022. Epidemiological, clinical, pathological characteristics, and survival were analyzed.

Results The mean age was 64.93± 13.817 years (range, 24–104 years) and 42.2% of patients were aged more than 70 years. From all, 13.5% of patients reported a history of lichen. The revealing symptom was a genital lump in 63% of cases. Clitoris was involved in 50.5% of cases. Tumors were classified as stage FIGO I, II, III, and IV in respectively 55.2%, 9.4%, 32.8%, and 2.6% of cases. Surgery was a radical vulvectomy, hemipelvectomy, and pelvic exenteration in respectively 96.4%, 2.1%, and 1.6% of cases. Lymph node (LN) dissection was bilateral in 88.5% of cases and the mean number of retrieved lymph LN was 14. We omitted LND in 2 cases staged IA. The mean tumor size was 42.21± 24.018 mm. Vulvar tumors were staged pT1,pT2, and pT3 respectively in 84.9%, 13.5%, and 1.6% of cases. LN metastasis (LNM) was assessed in 67 patients (34.9%) with bilateral invasion in 35.8% of cases and 3 or more LNM in 13.3%. Adjuvant radiotherapy was indicated in 39.1% of cases. With a mean follow-up time of 35.48±35.48 months, the 5-year overall survival and recurrence-free survival were 52.5% and 55.8% respectively, and were correlated to FIGO stage, LNR, and complete

Conclusion Vulvar cancer in Tunisia remains a rare disease, occurring mostly in elderly women and diagnosed at advanced stages. Our results suggest that a greater effort should be made to facilitate early diagnosis and treatment in order to improve survival.

Disclosures No potential conflict of interest